GSK PLC (GSK)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

2,113.00p

Buy

2,114.00p

arrow-up48.00p (+2.33%)

Prices updated at 01 Apr 2026, 13:19 BST
| Prices minimum 15 mins delay
|
Prices in GBX
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.
FTSE All-Share
arrow-up1.88%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Sir Jonathan Richard Symonds CBE
CEO
Mr. Luke Miels
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
66,841
Head office
79 New Oxford Street
London
United Kingdom
WC1A 1DG
mobile
+44 2080475000
letter
company.secretary@gsk.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Charles A. Bancroft
Non-Executive Director, Senior Independent Director
-
Sir Jonathan Richard Symonds CBE
Non-Executive Director, Chairman
-
Dr. Hal V Barron
Non-Executive Director
-
Ms. Wendy Becker
Non-Executive Director
-
Dr. Vishal Sikka
Non-Executive Director
-
Ms. Elizabeth McKee Anderson
Non-Executive Director
-
Dr. Anne Beal, M.D.,M.P.H.
Non-Executive Director
-
Dr. Harry C Dietz
Non-Executive Director
-
Dr. Jeannie Lee
Non-Executive Director
-
Dr. Gavin Screaton
Non-Executive Director
-
Ms. Julie Brown
Executive Director, Chief Financial Officer
-
Mr. Luke Miels
Executive Director, Chief Executive Officer
-
Mrs. Victoria Anne Whyte
Company Secretary
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Dodge & Cox95,731,640
Fidelity Management & Research Company LLC93,735,633
BlackRock Fund Advisors86,077,648
Vanguard76,113,587
Dodge & Cox International Stock Fund74,716,020

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
20 Mar 2026Purchase
18 Mar 2026Purchase
10 Mar 2026Purchase
10 Mar 2026Transfer in
20 Feb 2026Purchase
20 Feb 2026Purchase
13 Feb 2026Transfer in
13 Feb 2026Sale
10 Feb 2026Purchase
10 Feb 2026Transfer in
10 Feb 2026Transfer in
09 Feb 2026Sale of Option
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.